Isolation, characterization, and genomic analysis of a novel phage WSPA with lytic activity against Serratia

Lijuan Li1,2, Kunkun Li1,3, Yu Mi2

  • 1Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, College of Pharmacy, Dali University, Dali, Yunnan, China.

Microbiology Spectrum
|August 5, 2025
PubMed

Insights

A novel bacteriophage, Weishan phage (WSPA), effectively targets multidrug-resistant Serratia marcescens, offering a promising solution for hospital-acquired infections and environmental control.

Area of Science:

  • Microbiology
  • Virology
  • Genomics

Background:

  • Serratia marcescens is a significant cause of hospital-acquired infections, often forming biofilms on medical devices.
  • Controlling multidrug-resistant strains of S. marcescens is a critical challenge in healthcare settings.

Purpose of the Study:

  • To isolate and characterize a novel bacteriophage with potent activity against multidrug-resistant S. marcescens.
  • To evaluate the potential of this bacteriophage for therapeutic and biocontrol applications.

Main Methods:

  • Isolation of bacteriophage WSPA from the gut of Periplaneta americana L.
  • Comprehensive genomic and proteomic characterization of WSPA.
  • Assessment of WSPA's host range, stability, and growth characteristics.

Main Results:

  • WSPA, classified as a Muldoonvirus, possesses a double-stranded DNA genome and lacks virulence or antibiotic resistance genes.
  • Phage WSPA demonstrated potent lytic activity against multidrug-resistant S. marcescens strains.
  • WSPA exhibited favorable thermal and pH stability and a defined host range.

Conclusions:

  • Bacteriophage WSPA represents a novel and effective agent for controlling S. marcescens infections.
  • WSPA holds significant potential for phage therapy and biocontrol in healthcare environments.
  • This study expands phage resources and supports the development of phage libraries from medicinal insects.